Please go to the PowerPak homepage
and select a course.
Biomarkers in Immunotherapy Treatment Decision Making: Advancing Personalized Medicine in Oncology
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant Bristol-Myers Squibb.
Jennifer A. Wargo, MD, MMSc
Associate Professor, Surgical Oncology and Genomic Medicine
The University of Texas MD Anderson Cancer Center
Milena G. Wong, PharmD, BCOP
Clinical Pharmacy Specialist
Department of Pharmacy, Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Dr. Wargo has disclosed the following financial interests/arrangements or affiliations: Received grant/research support from: American Association for Cancer Research Stand Up to Cancer, Andrew Sabin Family Fellow Program, Department of Defense, MD Anderson Cancer Center's Melanoma Moon Shots Program, MD Anderson Cancer Center Multidisciplinary Research Program Grant, Melanoma Research Alliance, National Institutes of Health, Parker Institute for Cancer Immunotherapy at MD Anderson Cancer Center, and U.S.-Israel Binational Science Foundation; Consultant for: Astra-Zeneca, Biothera Pharma, Bristol-Myers Squibb, Glaxo Smith Klein, Merck, Merck Sharp and Dohme, Microbiome DX, Novartis, and Roche-Genentech; Served on a Speaker's Bureau for: Dava Oncology, Bristol-Myers Squibb, Gilead, Illumina, Imedex, MedImmune, and Omniprex; and Received other financial/material support from: Bristol-Myers Squibb, Glaxo Smith Klein, Novartis, and Roche-Genentech.
Dr. Wong has no actual or potential conflict of interest in relation to this program.
The clinical reviewer, Lisa Holle, PharmD, has no actual or potential conflict of interest in relation to this program.
Susanne Batesko, RN, BSN, Robin Soboti, R.Ph, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 1.0 hours (0.10 ceu)
Type of Activity: Knowledge
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 60 minutes
December 28, 2018
December 28, 2019
This accredited activity has been designed for oncology pharmacists and other pharmacists who manage or interact with oncology patients.
HOW TO EARN CREDIT
During the period December 28, 2018 through December 28, 2019 participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
To enhance oncology pharmacists' skills and knowledge in the use of biomarkers in immune-oncology treatment decision making, to personalize therapy thus optimizing care and outcomes.
Click below here to Download:
At the conclusion of this activity, the learner will be better able to:
- Describe the potential biomarkers being examined to predict response to immunotherapy, specifically immune checkpoint inhibitors
- Assess the variety of biomarker assessments available to determine biomarker status in patients
- Discuss strategies for the potential selection of immune checkpoint inhibitors in consideration of biomarkers in specific patient situations
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
All statements and opinions contained herein are solely those of the individual speakers and may not reflect those of The University of Texas MD Anderson Cancer Center.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Bristol-Myers Squibb. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.